Clinical Trials Logo

Filter by:
NCT ID: NCT02699749 Completed - Clinical trials for Nonhematologic Neoplasms, Advanced

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Start date: March 24, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and maximum tolerated dose (MTD) of TAK-931 in participants with advanced nonhematologic tumors.

NCT ID: NCT02699515 Completed - Solid Tumors Clinical Trials

MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors

Start date: March 11, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in subjects with metastatic or locally advanced solid tumors, for which no standard effective therapy exists or a standard therapy has failed.

NCT ID: NCT02697552 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Start date: March 2014
Phase: Phase 1
Study type: Interventional

Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered orally.

NCT ID: NCT02697058 Completed - Clinical trials for Metastatic Pancreatic Cancer

Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer

Start date: March 30, 2016
Phase: Phase 2
Study type: Interventional

Study Part 1: To assess the safety and tolerability, and to characterize the pharmacokinetics (PK) of BAX2398 in combination with 5-FU/calcium levofolinate in Japanese patients. Study Part 2: To compare the efficacy of BAX2398 in combination with 5-FU/calcium levofolinate versus 5-FU/calcium levofolinate as assessed by Progression Free Survival (PFS) using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

NCT ID: NCT02696798 Completed - Spondyloarthritis Clinical Trials

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

COAST-W
Start date: April 12, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).

NCT ID: NCT02696785 Completed - Spondyloarthritis Clinical Trials

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

COAST-V
Start date: May 2, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).

NCT ID: NCT02696265 Recruiting - Clinical trials for Chronic Atrial Fibrillation

CFAE/Spatiotemporal Dispersion Guided Ablation Versus PVI Guided Ablation in Persistent AF

CIPA
Start date: October 12, 2016
Phase: N/A
Study type: Interventional

Objective: The purpose of this study is to compare the efficacy and safety of ablation of Atrial Fibrillation (AF) drivers marked by spatiotemporal dispersions and Complex Fractionated Atrial Electrocardiograms (CFAEs) to Pulmonary Vein Isolation (PVI) based ablation in patients with persistent AF. Hypothesis: CFAE/spatiotemporal dispersion guided ablation will increase AF free survival compared to a PVI guided ablation. Patient population: Patients with persistent AF will be randomized based on a 2:1 ratio into one of two study arms: - CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation. - PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals

NCT ID: NCT02696031 Completed - Clinical trials for Non-radiographic Spondyloarthritis

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

PREVENT
Start date: April 29, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208

NCT ID: NCT02695420 Completed - Clinical trials for Heart Failure With Reduced Ejection Fraction

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Start date: April 14, 2016
Phase: Phase 2
Study type: Interventional

- To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction - To evaluate the safety and tolerability of oral omecamtiv mecarbil

NCT ID: NCT02695329 Completed - Clinical trials for Osteoarthritis, Knee

Vanguard TKA With KneeAlign 2 and Without KneeAlign 2

Start date: May 24, 2016
Phase: N/A
Study type: Interventional

Purpose of this study is to determine the effectiveness of the KneeAlign 2 system in terms of precise implant alignment by demonstrating that KneeAlign 2 provides better tibial alignment compared to conventional instruments